The record
FDA's 2022 talc sampling assignment tested 50 samples and asbestos was detected in none of them.
Claim scope
50 samples, zero positives. Confirmed against the published table: 50 distinct FDA Sample IDs, all rows 'negative'/'negative'.
What this source does not establish
Does not establish market-wide absence of asbestos; see detection-limit findings.
Limitations
Selection criteria included 'products marketed to children' and 'products marketed to women of color' — a targeted, not random, sample. Because the draw is non-random, the zero-positive result cannot be converted into a marketplace prevalence estimate in either direction.
Source
Gov Report — FDA Constituent Update, December 7, 2022 — 'FDA Releases Data from the Agency's 2022 Testing of Talc-Containing Cosmetic Products for Asbestos'; data table (FDA Sample IDs 01212022-1..14, 03022022-1..11, 03302022-1..13, 05022022-1..12)